Hindered by redundancies in the approval process, problems securing suitable data for clinical trials, and disparities in the drug classification system between China and other countries, foreign companies have rarely found it easy to navigate China’s
China Market Intelligence
Top Stories
On October 9, the China Insurance Regulatory Commission (CIRC) released the “Draft Provisions for Supervising Insurance Information,” with a public comment period open until October 31, 2015.
Enforcement of China’s Antimonopoly Law (AML)—an ongoing priority for the US-China Business Council (USCBC) and the business community—has remained prominent in recent bilateral discussions.
Following President Xi Jinping’s visit to the United States last month, the US and China announced a list of energy and environmental-related commitments aimed on cutting down on high-polluting, energy-intensive power and supporting the development of environmental technologies—presenting potential opportunities for co
US and Chinese negotiators are gearing up for a busy quarter as they head into bilateral and multilateral trade and investment talks.
The United States and China are gearing up for the upcoming Joint Commission on Commerce and Trade (JCCT) meetings in Guangzhou, scheduled for November 22-
China’s 13th Five Year Plan (FYP
China’s four free trade zones (FTZs)—the initial Shanghai FTZ and subsequent zones in Tianjin, Guangdong, and Fujian—offer companies a range of select market openings and preferential policies, while serving as a testing ground for reforms that eventually may be implemented nationwide.
This year has been a challenging one for China’s economy.
The State Council’s long-awaited framework for reforming China’s state-owned enterprises (SOEs) marks limited progress on areas of SOE reform such as mixed ownership, asset management, and SOE classification.